30 Day Trial

NuVasive Reports 3Q18 Revenue of $271.3MM, +9.6% vs. 3Q17

Share:

NuVasive performance driven by increased case volume and new products, posts 3Q18 revenue of US $271.3MM, +9.6%vs. 3Q17.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.